Možnosti ovlivnění kardiovaskulárního rizika u diabetes mellitus 2. typu antidiabetickou léčbou. Snížení kardiovaskulárního rizika při léčbě liraglutidem – výsledky studie LEADER
| Title in English | Possibilities of influencing cardiovascular risk in type 2 diabetes mellitus by antidiabetic treatment. Lowering of cardiovascular risk in treatment with liraglutide – Results of the LEADER |
|---|---|
| Authors | |
| Year of publication | 2016 |
| Type | Article in Periodical |
| Magazine / Source | Vnitřní lékařství |
| MU Faculty or unit | |
| Citation | |
| Field | Cardiovascular diseases incl. cardiosurgery |
| Keywords | cardiovascular risk; LEADER; liraglutid; type 2 diabetes mellitus |
| Description | The article summarizes current knowledge about the possibilities for influencing the cardiovascular risk in treatment of type 2 diabetes, especially focusing on the results of a prospective morbidity–mortality LEADER trial, which demonstrated the superiority of liraglutide in patients with very high cardiovascular risk. |